We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $6.37K invested in Bellerophon Therapeutics, Inc. in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

10.41% less ownership

Funds ownership: 10.41% → 0% (-10%)

91% less funds holding

Funds holding: 22 → 2 (-20)

99% less capital invested

Capital invested by funds: $507K → $6.37K (-$500K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 20

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-20
Holders Change %
-90.91%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$71.6K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$64.1K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$58K
4
BlackRock
BlackRock
New York
-$50.8K
5
Two Sigma Investments
Two Sigma Investments
New York
-$45.3K

BLPH Hedge Fund Activity: Q4 2023 in Review

2 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2023, worth a combined $6.37K — down 99% from $507K a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BLPH and 0 opened new positions — a net loss of 20 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Wells Fargo, exiting entirely with an estimated $71.6K sold.

  • 2 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2023, down from 22 in Q3 2023.
  • Funds reported $6.37K of Bellerophon Therapeutics, Inc. stock for Q4 2023, down 99% quarter-over-quarter.
  • 0 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2023 and 20 closed out, a net change of -20 holders.
  • The largest Bellerophon Therapeutics, Inc. seller in Q4 2023 was Wells Fargo, an estimated $71.6K sold.

Based on aggregated 13F filings for Q4 2023.